|
1
|
Hue SS, Oon ML, Wang S, Tan SY and Ng SB:
Epstein-Barr virus-associated T- and NK-cell lymphoproliferative
diseases: An update and diagnostic approach. Pathology. 52:111–127.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pavlasova G and Mraz M: The regulation and
function of CD20: An ‘enigma’ of B-cell biology and targeted
therapy. Haematologica. 105:1494–1506. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang Y, Wang K, Tan Q, Yang K, Wu D, Xu
Y, Zhao X and Jiang Z: Primary breast CD20-positive extranodal NK/T
cell lymphoma with stomach involvement: A case report and
literature review. Diagn Pathol. 16:1032021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang Y, Chen S, Wei R, Guo X, Yang X, Cao
Q, Yang Y and Yun J: CD20-positive extranodal NK/T cell lymphoma:
Clinicopathologic and prognostic features. Virchows Arch.
477:873–883. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cheng J, Zhu H and Choi JK: CD30
expression in pediatric neoplasms, study of 585 cases. Pediatr Dev
Pathol. 20:191–196. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pierce JM and Mehta A: Diagnostic,
prognostic and therapeutic role of CD30 in lymphoma. Expert Rev
Hematol. 10:29–37. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu ML, Gabali A, Hsi ED, Fedoriw Y, Vij K,
Salama ME, Ramchandren R, O'Malley D, Wick MR, Battistella M and
Gru AA: Practical approaches on CD30 detection and reporting in
lymphoma diagnosis. Am J Surg Pathol. 44:e1–e14. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kawamoto K, Miyoshi H, Suzuki T, Sasaki Y,
Yamada K, Yanagida E, Muto R, Kiryu M, Sone H, Seto M, et al:
Frequent expression of CD30 in extranodal NK/T-cell lymphoma:
Potential therapeutic target for anti-CD30 antibody-based therapy.
Hematol Oncol. 36:166–173. 2018. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim WY, Nam SJ, Kim S, Kim TM, Heo DS, Kim
CW and Jeon YK: Prognostic implications of CD30 expression in
extranodal natural killer/T-cell lymphoma according to treatment
modalities. Leuk Lymphoma. 56:1778–1786. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Morley-Jacob C and Gallop-Evans E: An
update on lymphoma in children and young adults. Paediatr Child
Health. 22:92–97. 2012. View Article : Google Scholar
|
|
11
|
Alaggio R, Amador C, Anagnostopoulos I,
Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D,
Calaminici M, et al: The 5th edition of the World Health
Organization classification of haematolymphoid tumours: Lymphoid
neoplasms. Leukemia. 36:1720–1748. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tse E and Kwong YL: The diagnosis and
management of NK/T-cell lymphomas. J Hematol Oncol. 10:852017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Feldman AL, Laurent C, Narbaitz M,
Nakamura S, Chan WC, de Leval L and Gaulard P: Classification and
diagnostic evaluation of nodal T- and NK-cell lymphomas. Virchows
Arch. 482:265–279. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Montes-Mojarro IA, Kim WY, Fend F and
Quintanilla-Martinez L: Epstein-Barr virus positive T and NK-cell
lymphoproliferations: Morphological features and differential
diagnosis. Semin Diagn Pathol. 37:32–46. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mundy-Bosse BL, Weigel C, Wu YZ, Abdelbaky
S, Youssef Y, Casas SB, Polley N, Ernst G, Young KA, McConnell KK,
et al: Identification and targeting of the developmental blockade
in extranodal natural killer/T-cell lymphoma. Blood Cancer Discov.
3:154–169. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim H and Ko YH: The pathologic and
genetic characteristics of extranodal NK/T-cell lymphoma. Life
(Basel). 12:732022.PubMed/NCBI
|
|
17
|
de Mel S, Hue SS, Jeyasekharan AD, Chng WJ
and Ng SB: Molecular pathogenic pathways in extranodal NK/T cell
lymphoma. J Hematol Oncol. 12:332019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang YH, Huang CT, Tan SY and Chuang SS:
Primary gastric extranodal natural killer/T-cell lymphoma, nasal
type, with acquisition of CD20 expression in the subcutaneous
relapse: Report of a case with literature review. J Clin Pathol.
68:943–945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shao SH, Wang Y, Dai XY, Xiao YJ, Guan JJ,
Lin DL, Wang JG, Li YJ, Xing XM and Zhao P: CD20-positive T cell
lymphoma: Clinicopathological features of five cases. Zhonghua Bing
Li Xue Za Zhi. 49:1021–1026. 2020.(In Chinese). PubMed/NCBI
|
|
20
|
Lee AYS: CD20+ T cells: An
emerging T cell subset in human pathology. Inflamm Res.
71:1181–1189. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jeon YK, Kim JH, Sung JY, Han JH and Ko
YH; Hematopathology Study Group of the Korean Society of
Pathologists, : Epstein-Barr virus-positive nodal T/NK-cell
lymphoma: an analysis of 15 cases with distinct clinicopathological
features. Hum Pathol. 46:981–990. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kato S, Asano N, Miyata-Takata T, Takata
K, Elsayed AA, Satou A, Takahashi E, Kinoshita T and Nakamura S:
T-cell receptor (TCR) phenotype of nodal Epstein-Barr virus
(EBV)-positive cytotoxic T-cell lymphoma (CTL): A clinicopathologic
study of 39 cases. Am J Surg Pathol. 39:462–471. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim SJ, Park S, Kang ES, Choi JY, Lim DH,
Ko YH and Kim WS: Induction treatment with SMILE and consolidation
with autologous stem cell transplantation for newly diagnosed stage
IV extranodal natural killer/T-cell lymphoma patients. Ann Hematol.
94:71–78. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shen Z, Wang Y, Xie R, Zhang Q, Xing X,
Zhang S, Liu H and Sang W: Clinicopathologic features and survival
outcomes of CD30 expression in extranodal natural killer/T-cell
lymphoma. Am J Clin Pathol. 162:95–102. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li P, Jiang L, Zhang X, Liu J and Wang H:
CD30 expression is a novel prognostic indicator in extranodal
natural killer/T-cell lymphoma, nasal type. BMC Cancer. 14:8902014.
View Article : Google Scholar : PubMed/NCBI
|
